● Recruiting

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Condition: Breast Cancer · Sponsor: Regina Elena Cancer Institute

PhaseN/A

Planned participants160

Who can joinFemale, N/A to no upper limit

Healthy volunteersNo

About this study

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

This description comes directly from the study's public registry record.

Talk to the study team

Patrizia Vici, Doctor · +39 06-5266.5698 · patrizia.vici@ifo.it

Always discuss trial participation with your own doctor first.

Locations (1)

"Regina Elena" National Cancer Institute

Rome, Rome, Italy

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06272799